Movano Inc
NASDAQ:MOVE

  • LAST PRICE
    3.4400
  • TODAY'S CHANGE (%)
    0.2600 (8.1761%)
  • Bid / Lots
    3.1200/ 1
  • Ask / Lots
    4.0000/ 16
  • Open / Previous Close
    3.1213 / 3.1800
  • Day Range
    3.0500
    3.4929
  • 52 Week Range
    2.8000
    14.7000
  • Volume
    8,242

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 14, 2024

      Show headlines and story abstract

    • 4:07PM ET on Thursday Nov 14, 2024 by MT Newswires
      Companies Mentioned: MOVE
      04:07 PM EST, 11/14/2024 (MT Newswires) -- ...

    • 4:05PM ET on Thursday Nov 14, 2024 by PR Newswire
      Companies Mentioned: MOVE

      Highlights successful Evie Ring back-in-stock execution

      Updates status of EvieMED 510(k) application review

      Focuses on launch of EvieMED and securing B2B opportunities

      Conference Call at 2:00 PM PT/ 5:00 PM ET Today

    • 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: MOVE
      liability -- 23 Other noncurrent liabilities 583 50 ----------- ---------- Total noncurrent liabilities 583 73 ----------- ---------- Total liabilities 4,816 5,972 ----------- ---------- Stockholders' equity: Common stock 10 6 Additional paid-in capital 153,732 127,823 Accumulated deficit (143,491) (124,380) ----------- ---------- Total stockholders' equity 10,251 3,449 ----------- ---------- Total liabilities and stockholders' equity $ 15,067 $ 9,421 =========== ========== Movano Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, ---------------------- ---------------------- 2024 2023 2024 2023 ---------- ---------- ---------- ---------- Revenue $ 50 $ -- $ 902 $ -- COSTS AND EXPENSES: Cost of revenue 845 -- 2,440 -- Research and development 3,404 5,636 9,198 13,701 Sales, general and administrative 3,180 3,443 8,794 9,965 --------- --------- --------- --------- Total costs and expenses 7,429 9,079 20,432 23,666 --------- --------- --------- --------- Loss from operations (7,379) (9,079) (19,530) (23,666) --------- --------- --------- --------- Other income (expense), net: Interest and other income, net 178 117 419 341 --------- --------- --------- --------- Other income (expense), net 178 117 419 341 --------- --------- --------- --------- Net loss and total comprehensive loss $ (7,201) $ (8,962) $ (19,111) $ (23,325) ========= ========= ========= ========= Net loss per share, basic and diluted $ (1.06) $ (2.65) $ (3.33) $ (7.99) ========= ========= ========= ========= Weighted average shares used in computing net loss per share, basic and diluted 6,816,339 3,380,763 5,733,007 2,921,201 ========= ========= ========= =========

    • 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: MOVE
      liability -- 23 Other noncurrent liabilities 583 50 ----------- ---------- Total noncurrent liabilities 583 73 ----------- ---------- Total liabilities 4,816 5,972 ----------- ---------- Stockholders' equity: Common stock 10 6 Additional paid-in capital 153,732 127,823 Accumulated deficit (143,491) (124,380) ----------- ---------- Total stockholders' equity 10,251 3,449 ----------- ---------- Total liabilities and stockholders' equity $ 15,067 $ 9,421 =========== ========== Movano Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, ---------------------- ---------------------- 2024 2023 2024 2023 ---------- ---------- ---------- ---------- Revenue $ 50 $ -- $ 902 $ -- COSTS AND EXPENSES: Cost of revenue 845 -- 2,440 -- Research and development 3,404 5,636 9,198 13,701 Sales, general and administrative 3,180 3,443 8,794 9,965 --------- --------- --------- --------- Total costs and expenses 7,429 9,079 20,432 23,666 --------- --------- --------- --------- Loss from operations (7,379) (9,079) (19,530) (23,666) --------- --------- --------- --------- Other income (expense), net: Interest and other income, net 178 117 419 341 --------- --------- --------- --------- Other income (expense), net 178 117 419 341 --------- --------- --------- --------- Net loss and total comprehensive loss $ (7,201) $ (8,962) $ (19,111) $ (23,325) ========= ========= ========= ========= Net loss per share, basic and diluted $ (1.06) $ (2.65) $ (3.33) $ (7.99) ========= ========= ========= ========= Weighted average shares used in computing net loss per share, basic and diluted 6,816,339 3,380,763 5,733,007 2,921,201 ========= ========= ========= =========

  • Nov 7, 2024

      Show headlines and story abstract

    • 8:01AM ET on Thursday Nov 07, 2024 by PR Newswire
      Companies Mentioned: MOVE

      New hardware boasts significant improvements to reduce noise and generate higher fidelity signals

      Movano Health Inc. (Nasdaq: MOVE) announced today that it has tested its newly developed blood pressure wrist wearable as part of its November 5th and 6thhypoxia clinical trial that took place at the University of California, San Francisco. The updated device features an additional 12 mmWave antennas which together with Movano Health's custom IC delivers enhanced data collection with less impact of placement while also featuring a slimmer design, making it easier and more comfortable to wear. In addition, the new wearable monitors a host of other vital signs including pulse rate, blood oxygen saturation (Sp02), respiration rate and ECG waveforms.

Peers Headlines